Alcami Corporation Appoints Tori E. Arens as New President of Drug Product
Alcami Corporation, a prominent contract development and manufacturing organization (CDMO), is excited to announce the appointment of Tori E. Arens to the position of President of Drug Product. With over 25 years of experience in the pharmaceutical industry, Tori brings a wealth of knowledge and expertise, particularly in drug development and manufacturing processes.
This strategic move comes at a time when Alcami is looking to bolster its drug product manufacturing capabilities. Under Tori's leadership, the company will oversee two essential sterile fill-finish facilities located in Research Triangle Park, North Carolina, and Charleston, South Carolina. Additionally, her role will encompass the management of oral solid dose drug product manufacturing, along with packaging and labeling operations in Wilmington, North Carolina.
Patrick Walsh, the Chairman and Interim CEO of Alcami, emphasized Tori's unique blend of manufacturing expertise and strong leadership qualities, remarking that these attributes will be invaluable for Alcami, its customers, and the patients they serve. Tori’s previous roles include serving as Vice President and General Manager at Resilience for their gene therapy viral vector manufacturing operations. She has also held significant positions at Aerie Pharmaceuticals, Biogen, and Eisai, Inc., showcasing her extensive leadership skills and strategic insight in the pharmaceutical sector.
Tori Arens earned both her Master of Science in Pharmaceutics and her Bachelor of Arts in Chemistry from the University of North Carolina at Chapel Hill. Her academic background complements her considerable industry experience, positioning her well to lead Alcami's Drug Product division.
In a statement, Tori expressed her enthusiasm for joining Alcami at this dynamic juncture. "I'm thrilled to join Alcami during this exciting period of growth and to collaborate with such a talented team," she stated. "Alcami's vision, mission, and values deeply resonate with me, and I look forward to leading this area of operations to drive continued success and serve patients worldwide."
Alcami Corporation, headquartered in North Carolina, boasts over 45 years of experience in advancing pharmaceuticals and biologics from development through to delivery. The company provides an array of fully integrated lab services, drug product manufacturing, and cGMP pharmaceutical storage, as well as support services that include environmental monitoring, calibration, and validation. With strong backing from private equity firms including GHO Capital, The Vistria Group, and Ampersand Capital Partners, Alcami is poised for ongoing growth and innovation in the life sciences sector.
This new appointment comes as part of Alcami's commitment to fortifying its position as a leader in the pharmaceutical manufacturing industry. With Tori E. Arens at the helm of Drug Product, the organization is strategically aligning itself for future advancements and enhanced service capacity in drug development and manufacturing processes.
For more information about Alcami and its offerings, you can visit their website at alcami.com.
With these significant developments, Alcami Corporation is clearly focused on achieving new heights and continues to elevate its impact in the commercial pharmaceutical landscape.
This strategic move comes at a time when Alcami is looking to bolster its drug product manufacturing capabilities. Under Tori's leadership, the company will oversee two essential sterile fill-finish facilities located in Research Triangle Park, North Carolina, and Charleston, South Carolina. Additionally, her role will encompass the management of oral solid dose drug product manufacturing, along with packaging and labeling operations in Wilmington, North Carolina.
Patrick Walsh, the Chairman and Interim CEO of Alcami, emphasized Tori's unique blend of manufacturing expertise and strong leadership qualities, remarking that these attributes will be invaluable for Alcami, its customers, and the patients they serve. Tori’s previous roles include serving as Vice President and General Manager at Resilience for their gene therapy viral vector manufacturing operations. She has also held significant positions at Aerie Pharmaceuticals, Biogen, and Eisai, Inc., showcasing her extensive leadership skills and strategic insight in the pharmaceutical sector.
Tori Arens earned both her Master of Science in Pharmaceutics and her Bachelor of Arts in Chemistry from the University of North Carolina at Chapel Hill. Her academic background complements her considerable industry experience, positioning her well to lead Alcami's Drug Product division.
In a statement, Tori expressed her enthusiasm for joining Alcami at this dynamic juncture. "I'm thrilled to join Alcami during this exciting period of growth and to collaborate with such a talented team," she stated. "Alcami's vision, mission, and values deeply resonate with me, and I look forward to leading this area of operations to drive continued success and serve patients worldwide."
Alcami Corporation, headquartered in North Carolina, boasts over 45 years of experience in advancing pharmaceuticals and biologics from development through to delivery. The company provides an array of fully integrated lab services, drug product manufacturing, and cGMP pharmaceutical storage, as well as support services that include environmental monitoring, calibration, and validation. With strong backing from private equity firms including GHO Capital, The Vistria Group, and Ampersand Capital Partners, Alcami is poised for ongoing growth and innovation in the life sciences sector.
This new appointment comes as part of Alcami's commitment to fortifying its position as a leader in the pharmaceutical manufacturing industry. With Tori E. Arens at the helm of Drug Product, the organization is strategically aligning itself for future advancements and enhanced service capacity in drug development and manufacturing processes.
For more information about Alcami and its offerings, you can visit their website at alcami.com.
With these significant developments, Alcami Corporation is clearly focused on achieving new heights and continues to elevate its impact in the commercial pharmaceutical landscape.
Topics Business Technology）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.